本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗,我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示,便表示您已接受我們的網站使用條款。 關閉
KYOTO, Japan, Sept. 26, 2024 /PRNewswire/ -- - Making GaN Easy to Use: Engineering Challenges from R&D to Practical Application - ROHM Co., Ltd. has released the sixth German-language installment in the "Stories of Manufacturing" series of short films, this time taking viewers behind the scenes at the development of GaN devices, which are attracting attention as next-generation power semiconductors. Actively involved since the 2000s in the research and development of power semiconductors using GaN, ROHM developed in 2022 proprietary GaN HEMTs that leverage the strengths of the company's vertically integrated production system. Furthermore, it has developed the Power Stage IC that combines a dedicated gate driver IC and a GaN HEMT in a single package, offering a cost-effective solution for GaN devices that have historically presented challenges. In addition, they contribute to lower power consumption and miniaturization in a range of fields, from fast chargers and data centers to on-board chargers for xEVs. This latest short film showcases the technical challenges and development stories leading up to the mass production of GaN devices and gate driver ICs. This video can be viewed on ROHM's official website and YouTube channel. Logo:https://cdn.kyodonewsprwire.jp/prwfile/release/M106254/202409196667/_prw_PI1fl_oeubbmLk.jpg Film image:https://cdn.kyodonewsprwire.jp/prwfile/release/M106254/202409196667/_prw_PI2fl_3gBAsy5q.jpg "Stories of Manufacturing"In Stories of Manufacturing, ROHM uncovers the passion that its developers have for manufacturing and delves into the behind-the-scenes stories of their projects in the form of interviews, showcasing how it consistently supplies high-quality products, with "quality first" and "vertically integrated production system" as common concepts. StoriesHow well can we use data? This is where skill comes in -- Quality Division Analysis CenterThe first in the industry, which was a challenge in itself -- Developing Flexible LinesFor everyone who loves music -- the Birth of MUS-IC -- Audio Device DevelopmentTransforming ROHM's unique "strengths" into "trust" -- Wafer Production ProcessThe endless struggle against invisible noise -- EMC Countermeasure DesignGaN paves the way to carbon neutrality -- GaN Power Semiconductor Devices - EnglishWebsite: https://www.rohm.com/company/about/stories-of-manufacturing/ganYouTube: https://youtube.com/playlist?list=PL0xO9BAX82ePYc-njfvi5BxyWlrpqvcFA&si=J_bK-pNSCqQYjJAQ - GermanWebsite: https://www.rohm.de/company/about/stories-of-manufacturing/ganYouTube: https://youtube.com/playlist?list=PL0W_pMg_e_JMXNTeZuZU5pgJbh6IxazKd&si=UqfPL-eo9gvhlAs9 Languages supported:English, German, Japanese Official website: https://www.rohm.com/ About ROHM: https://kyodonewsprwire.jp/attach/202409196667-O1-rp1xd7tc.pdf
In Phase Ia clinical study, GZR4 demonstrated favorable safety and tolerability profiles in healthy subjects, maintaining a stable glucose-lowering effect for up to one week with a single administration. In Phase Ib clinical study, patients with Type 2 diabetes mellitus (T2DM) receiving six weeks of GZR4 treatment were safe and well tolerated. GZR4 also exhibited improvements in fasting blood glucose (FBG), glycated hemoglobin (HbA1c), and time in range (TIR) across all dosage groups, outperforming the insulin degludec (IDeg) group. BEIJING, Sept. 14, 2024 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced the clinical results from two Phase I trials of the Company's independently developed novel once-weekly insulin analog, GZR4, in healthy Chinese subjects and patients with T2DM in oral presentation and short oral discussion at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024). Statement:1. GZR18 injection is an investigational drug and has not yet been approved in China.2. Gan & Lee Pharmaceuticals does not recommend the use of any unapproved drugs/indications. Phase Ia Study Results This placebo-controlled and active-comparator-controlled, single-center, single-dose, randomized, dose-escalation study aimed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GZR4 in healthy adult male participants. The study was conducted following a dose-escalation design, starting from lower doses and progressively increasing to higher doses. Participants in cohorts 1-4 randomly receiving a subcutaneous injection of GZR4 (1, 3, 6, or 12 nmol/kg) or placebo, while cohort 5 received a single dose of 0.4 U/kg (2.4 nmol/kg) insulin degludec (IDeg) as an active comparator. A 24-hour glucose clamp procedure was conducted on days 2 and 7 respectively post-GZR4 administration in cohorts 2-4, and on day 1 post-IDeg administration in cohort 5. GZR4 exhibited favorable safety and tolerability in healthy subjects, with no serious adverse events (SAEs) reported, and no discontinuations due to the investigational product-related adverse events. PD results indicated that the glucose infusion rate (GIR) on day 7 was approximately 80% of that on day 2 in subjects receiving 12 nmol/kg GZR4, indicating that the glucose-lowering effect of GZR4 persists for approximately one week. Meanwhile, the area under the GIR-time curve on day 2 (AUCGIR,24-48h) and day 7 (AUCGIR,144-168h) for the 6 nmol/kg dose of GZR4 was similar to the 24-hour GIR (AUCGIR,0-24h) for the 0.4 U/kg (2.4 nmol/kg) of IDeg (37.84 ± 9.86 versus 40.60 ± 14.39 h*mg/kg/min, respectively)*, implying that the average daily glucose-lowering effect of GZR4 is comparable to that of IDeg. Convert accordingly, it is estimated that the potency of GZR4 is approximately 2.5-fold greater than that of IDeg when evaluating based on a similar molar concentration. Phase Ib Study Results In this randomized, open-label, active-controlled, multi-center, dose-escalation Phase Ib trial, a total of 36 patients with T2DM who had previously been treated with basal insulin were randomized in a 3:1 ratio to receive a fixed once-weekly dose of GZR4 (6, 8, or 12 nmol/kg) or once-daily (IDeg) (equal to the pre-enrolment daily basal insulin dosage) for 6 weeks. PK results showed that the maximum plasma concentration (Cmax) of GZR4 increased dose-dependently, while the time to maximum concentration (Tmax) and half-life were approximately 32 hours and 135 hours at steady state, respectively. PD data indicated dose-dependent reductions in FBG (-1.77 ± 0.20, -2.03 ± 0.66, and -2.75 ± 0.71 mmol/L for GZR4 in 6, 8, and 12 nmol/kg groups, respectively) in week 6, which outperformed the IDeg group (-1.12 ± 0.36 mmol/L*). After 6 weeks of treatment, the 6 nmol/kg GZR4 group demonstrated a reduction in HbA1c of 0.76 ± 0.14%, compared to the reduction of 0.13 ± 0.21% * in the IDeg group. In patients with T2DM, GZR4 demonstrated good safety and tolerability. No serious adverse events were reported in all treatment groups; the most frequently reported treatment-emergent adverse event was hypoglycaemia, but no severe hypoglycemia occurred. The detailed results of the Phase I studies will be published in a peer-reviewed journal. *Trial data are presented as mean ± standard error. Gan & Lee Pharmaceuticals also announced announced that a multicenter, randomized, open-label, parallel-control, treat-to-target phase 2 study is underway in patients with T2DM who have inadequate glycemic control with oral antidiabetic drugs, including insulin-naïve patients and patients on basal insulin. The study enrolled 179 adult participants and compares the efficacy and safety of once-weekly GZR4 with once-daily insulin degludec. All participants have completed treatment, and preliminary results are promising, further validating the findings from the Phase I studies. Dr. Gan Zhong-ru, Chairman of Gan & Lee Pharmaceuticals, commented: "A significant number of patients with Type 2 diabetes mellitus are experiencing delays in initiating insulin therapy and exhibit poor long-term adherence to treatment,etc. The introduction of weekly insulin preparations has the potential to significantly improve the aforementioned challenges. The completed Phase I trials confirmed GZR4's ability to provide stable glycemic control for a full week with a single dose, along with favorable safety and tolerability profiles. In addition, GZR4 is expected to reduce the weekly dosage of insulin required reaching the glycemic target, thereby reducing the possible risk of hypoglycaemia. We look forward to continuing to explore the clinical benefits of GZR4 in future trials." About Gan & Lee Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine®). In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked second overall and first among domestic companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee's competitiveness in both international and domestic markets. In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas. Forward-looking statements Forward-looking statements are based on our expectations and assumptions as of the date of the statements. Actual results may differ materially from those expressed in these forward-looking statements due to a variety of factors, and we can give no assurance that such results will be achieved in the future. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Further Information: BPRD@ganlee.com (Media)BD@ganlee.com (Business Development)info.medical@ganlee.com (Medical Information)
Obese and overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean percent changes in body weight from baseline of -11.15%, -13.22%, -14.25%, -17.29%, and -17.78%, respectively, with the placebo group at -0.99%; and at 30 weeks, participants' body weight continued to decrease. The clinical efficacy and safety of bi-weekly 48 mg and once-weekly 24 mg GZR18 injections were comparable, with no significant difference in mean percent change in body weight from baseline between the two groups (one-sided test, P > 0.025). GZR18 injections were safe and well tolerated, with the most commonly reported adverse events being gastrointestinal reactions, comparable to similar drugs. BEIJING, July 22, 2024 /PRNewswire/ -- Recently, Gan & Lee Pharmaceuticals(Gan & Lee, Shanghai Stock Exchange: 603087) announced that its independently developed long-acting GLP-1 receptor agonist (GLP-1 RA), GZR18 injection, has achieved positive results in a clinical trial for adults with obesity/overweight in China. Statement: 1. GZR18 injection is an investigational drug and has not yet been approved in China. 2. Gan & Lee Pharmaceuticals does not recommend the use of any unapproved drugs/indications. The phase IIb clinical trial (CTR20231695) is a multi-center, randomized, double-blind, placebo-controlled study conducted at 25 clinical trial centers in China, recruiting a total of 340 participants. The participants were overweight (BMI≥24 kg/m2) with at least one weight-related comorbidity or obese (BMI≥28 kg/m2) adults with poorly controlled diet and exercise. They were randomized to receive bi-weekly (Q2W) doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly (QW) dose of 24 mg GZR18 injection or placebo for 30 weeks (including a dose escalation period). The primary efficacy endpoint of the study was the percent change in body weight from baseline after 30 weeks of treatment. The study assessed changes from baseline in average weight, waist circumference, waist-to-hip ratio, body mass index (BMI), glycemic parameters, and the safety and tolerability of the drug. After 30 weeks of treatment, compared to the placebo group, participants receiving different doses and frequencies of GZR18 injection (12 mg, 18 mg, 24 mg, and 48 mg Q2W; 24 mg QW) had a significant reduction in the percent change in body weight from baseline. The mean percent changes in body weight from baseline was -11.15% (12 mg group, Q2W), -13.22% (18 mg group, Q2W), -14.25% (24 mg group, Q2W), -17.29% (48 mg group, Q2W), and -17.78% (24 mg group, QW), all more effective than the placebo group (reduced by 0.99%). There was no significant difference in mean percent change in body weight between the 48 mg Q2W group and the 24 mg QW group (one-sided test, P > 0.025). In this study, the bi-weekly GZR18 injections were generally safe and well tolerated, consistent with the known safety signals of GLP-1 receptor agonists. The most common adverse events were gastrointestinal reactions, most of which were mild to moderate in severity, comparable to other GLP-1 RAs. The comprehensive results of this phase IIb study are planned to be announced later this year and will be published in a peer-reviewed journal. About Gan & Lee Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine®). In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked second overall and first among domestic companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee's competitiveness in both international and domestic markets. In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas. Further Information: BPRD@ganlee.com (Media) BD@ganlee.com (Business Development)
BEIJING and BRIDGEWATER, N.J., June 23, 2024 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced the results of the Phase 1b/2a clinical study of the Company's independently developed glucagon-like peptide-1 (GLP-1) receptor agonist, GZR18 Injection, in an obese/overweight population in China, along with the results of two other innovative insulins' preclinical studies in poster presentations at the American Diabetes Association's(ADA's)84th Scientific Sessions. This randomized, double-blind, placebo-controlled, dose-escalation Phase 1b/2a clinical study evaluated the safety, tolerability, pharmacokinetics and efficacy of GZR18 Injection in Chinese subjects with obesity/overweight after multiple administration on a once-weekly (QW) or bi-weekly (Q2W) dosing interval. A total of 36 obese participants were enrolled in the study and randomized in a 3:1 ratio to receive a dose titration of 1.5 mg to 30 mg of GZR18 Injection or a matching placebo for a total of 35 weeks. The study results demonstrated a superior efficacy of GZR18 Injection than placebo for weight reduction in Chinese obese subjects. After 35 weeks of treatment, the mean weight change from baseline in the GZR18 QW group was -16.5 kg (95% CI: -19.9 kg, -13.1 kg); the placebo-adjusted mean percent weight change from baseline was -18.6% (95% CI: -25.5%, -11.6%). Although it was not a head-to-head study, when compared to the published data on weight reduction of similar products currently available on the market, GZR18's weight-reducing ability outperformed Semaglutide and dual-incretin receptor targeted Tirzepatide in similar study duration. Meanwhile, the mean weight change from baseline in the GZR18 Q2W group was -11.3 kg (95% CI: -15.4 kg, -7.2 kg); the placebo-adjusted mean percent weight change from baseline was -13.5% (95% CI: -21.0%, -6.0%). In addition, the percentage of participants achieving weight reductions of ≥5%, 10%, and 15% from baseline were 100.0%, 90.0%, and 80.0%, respectively, in the GZR18 QW group, and the percentage of participants achieving weight reductions of ≥5%, 10%, and 15% from baseline were 71.4%, 71.4%, and 42.9%, respectively, in the GZR18 Q2W group. No participant in the placebo group achieved a weight reduction of 5% and above. In terms of safety, GZR18 Injection was well tolerated in obese participants. The most commonly reported adverse events (AE) during treatment were gastrointestinal related AEs, and all were mild to moderate in severity. This is consistent with the incretin-based therapies approved for the treatment of obesity and overweight and occurred mainly in the early dose-escalation period. There were no serious hypoglycemic events in this study and no serious adverse events related to the investigational drug. Gan & Lee also announced that a multi-center, placebo-controlled, randomized, double-blind, 30-week Phase 2 clinical study evaluating the efficacy and safety of GZR18 Injection in Chinese adults with obesity and overweight is in progress. A total of 338 adults with obesity or overweight were enrolled in this study, and the study explores a broader dose range and frequency of administration. The main body of the Phase 2 has now been completed, and the priliminary study data further support the results of the reported Phase 1b/2a obese/overweight study, particularly the positive results achieved with bi-weekly dosing frequency. "We are very excited about the clinical results of the GZR18 program to the present day." Dr. Gan Zhong-ru, Founder of Gan & Lee, commented. "Our unique molecular design delays the onset of drug action and attenuates the peak effect, thereby improving drug tolerability and achieving smooth and sustained weight loss in a stepwise manner. Moreover, GZR18 has a longer duration of action, which is expected to be administered once every two weeks. Meanwhile, we hope that the clinical results of GZR18 will provide more evidence to reveal the mechanism of action of different targets of Incretins and Glucagon." In addition, Gan & Lee announced the results of preclinical trials of the company's investigational products: GZR4, a once-weekly insulin analog, and GZR101, a premixed dual insulin analog, at the ADA's 84th Scientific Sessions: Once-weekly Insulin Analog GZR4 GZR4 is a novel ultra-long-acting basal insulin analog designed for once-weekly administration. Results from preclinical studies have shown that GZR4 has a significantly higher affinity for human serum albumin (HSA) and a significantly lower affinity for the insulin receptor than insulin Icodec, another once-weekly insulin analog. Moreover, unlike insulin Icodec, GZR4 maintains its activity in activating the insulin receptor after binding to albumin. In the studies using animal models of diabetes, the glucose-lowering effect of GZR4 was observed to be 2-3 times greater than that of insulin Icodec. Based on the preclinical results, GZR4 is expected to be the fourth-generation basal insulin that can be administered once a week to achieve an effective glycemic control. Premixed Insulin Analog GZR101 GZR101 injection is a premixed insulin analog made from a combination of ultra-long-acting basal insulin GZR33 injection and rapid-acting insulin aspart (Rapilin®). Different from traditional premixed insulin analogs, the duration of glucose-lowering effect of basal insulin component (GZR33) in GZR101 can last 72 hours, and there is no significant peak within 24 hours after reaching a steady state with multiple injections. When combined with insulin aspart (Rapilin®️) to make a premixed insulin analog, it can achieve smooth control of fasting and postprandial blood glucose throughout the day. In diabetic animal models, GZR101 is significantly superior than insulin degludec/insulin aspart (IDegAsp) in blood glucose reduction and safety. As a premixed insulin analog developed based on an advanced concept, GZR101 is expected to make an important contribution to the control of blood glucose and the reduction of the risk of hypoglycemia in patients with diabetes globally. Conclusions and Future DirectionsThe ADA's 84th scientific sessions highlighted Gan & Lee Pharmaceuticals' leadership in developing next-generation diabetes and obesity treatments. With these latest preclinical and clinical results, the Company will continue to advance the development of innovative therapeutics for diabetes. While ongoing studies and upcoming trials will further support the positive influence of these innovative medicines on public health issues related to diabetes and obesity. Forward-looking StatementsForward-looking statements are based on our expectations and assumptions as of the date of the statements. Actual results may differ materially from those expressed in these forward-looking statements due to a variety of factors, and we can give no assurance that such results will be achieved in the future. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. References: American Diabetes Association. https://diabetes.org/ ADA's 84th Scientific Sessions. https://professional.diabetes.org/scientific-sessions About Gan & LeeGan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine®). In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked second overall and first among domestic companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee's competitiveness in both international and domestic markets. In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas. Further Information: BPRD@ganlee.com (Media)BD@ganlee.com (Business Development)
韓國首爾2024年6月19日 /美通社/ -- 韓國8英吋晶圓代工廠SK啟方半導體(SK keyfoundry)今日宣佈,已確保新一代功率半導體GaN(氮化鎵)的關鍵器件特性。該公司正在加大GaN的開發力度,力爭在年內完成開發工作。 SK啟方半導體還持續關注着GaN功率半導體的市場性和潛力。為此,該公司於2022年成立了一個專職團隊來推動GaN工藝的開發。日前,公司已得到650V GaN HEMT的新器件特性,並計劃在今年年底完成開發工作。 由於650V GaN HEMT具有較高的功率效率,因此與硅基產品相比,可以降低散熱器的成本。也正因如此,與硅基產品相比,終端客戶系統的價格差異較小。該公司預計,硅基650V產品將為快速充電適配器、LED照明、數據中心和ESS以及太陽能微型逆變器等市場的無晶圓廠客戶帶來開發優質產品的優勢。除了爭取新客戶外,SK啟方半導體還計劃積極向對650V GaN HEMT技術感興趣的現有功率半導體工藝客戶推廣該技術。 GaN具有高速開關、低導通電阻等特性,與硅基半導體相比,具備低損耗、高效率和小型化的優越特性,因此被稱為新一代功率半導體。據市場調研公司OMDIA預測,GaN功率半導體市場將以33%的復合年增長率增長,從2023年的5億美元增至2032年的64億美元,主要用於電源、混合動力與電動汽車以及太陽能逆變器。 SK啟方半導體表示,公司計劃以650V GaN HEMT為基礎,打造GaN產品組合,可為GaN HEMT和GaN IC提供多種電壓。 SK啟方半導體首席執行官Derek D. Lee表示:「除了具有競爭力的高壓BCD外,我們還在為下一代功率半導體做準備。我們還將擴大功率半導體產品組合,未來除GaN以外,還將包括SiC(碳化硅),以確立我們作為專業功率半導體代工廠的地位。」 關於SK啟方半導體 SK啟方半導體總部位於韓國,為半導體公司提供專業的模擬和混合信號代工服務,廣泛應用於消費、通信、計算、汽車及工業行業等領域。憑借廣泛的技術組合和工藝節點,SK啟方半導體有能力靈活滿足全球半導體公司不斷發展的需求。瞭解更多信息,請訪問https://www.skkeyfoundry.com。
SEOUL, South Korea, June 19, 2024 /PRNewswire/ -- SK keyfoundry, an 8-inch pure-play foundry in Korea, announced today that it has secured key device characteristics for a next-generation power semiconductor, GaN (gallium nitride). The company is intensifying its efforts for the development of GaN and striving to complete it within the year. Furthermore, SK keyfoundry has maintained a steadfast focus on the marketability and potential of GaN power semiconductors. To this end, the company formed a dedicated team in 2022 to drive the GaN process development. Recently, the company has secured new device characteristics of 650V GaN HEMT, and targets to finalize the development by the end of the year. As 650V GaN HEMTs have high power efficiency, they reduce the cost of heat sinks compared to silicon-based products. This results in a less significant difference in price for end customers' systems compared to silicon-based products. The company expects that the silicon-based 650V product will provide fabless customers in markets such as fast charging adapters, LED lighting, data centers and ESS, and solar microinverters with an advantage in developing premium products. In addition to securing new customers, SK keyfoundry plans to actively promote its 650V GaN HEMTs to a number of existing power semiconductor process-using customers who have expressed their interests in the technology. GaN has been referred as the next generation of power semiconductors because of its high-speed switching and low ON resistance characteristics, which enable lower loss, higher efficiency, and miniaturization than silicon-based semiconductors. The GaN power semiconductor market is expected to grow at a CAGR of 33% from $500 million in 2023 to $6.4 billion in 2032, according to a market research firm OMDIA, and will be primarily used in power supplies, hybrid and electric vehicles, and solar power inverters. SK keyfoundry said based on the 650V GaN HEMT, it plans to build a GaN portforlio that can offer a wide range of voltages for GaN HEMTs and GaN ICs. "We are preparing for the next generation of power semiconductors in addition to our competitive high-voltage BCDs," said Derek D. Lee, CEO of SK keyfoundry. "We will also expand our power semiconductor portfolio to include not only GaN but also SiC in the future to establish ourselves as a specialized power semiconductor foundry." About SK keyfoundry Headquartered in Korea, SK keyfoundry provides specialty Analog and Mixed-Signal foundry services for semiconductor companies to serve a wide range of applications in the consumer, communications, computing, automotive and industrial industries. With a broad range of technology portfolios and process nodes, SK keyfoundry has the flexibility and capability to meet the ever-evolving needs of semiconductor companies across the globe. Please visit https://www.skkeyfoundry.com for more information.
A12 藝術空間
gan
請先登入後才能發佈新聞。
還不是會員嗎?立即 加入台灣產經新聞網會員 ,使用免費新聞發佈服務。 (服務項目) (投稿規範)